IRB Reform Is Low-Hanging Fruit For FDA-Duke Clinical Trial Initiative
This article was originally published in The Gray Sheet
Executive Summary
One of the first jobs for a new FDA/Duke University partnership aimed at modernizing clinical trials will be reforming policies for institutional review boards so studies can get off the ground more quickly, participants say